Intellia Therapeutics (NTLA) Enterprise Value (2016 - 2026)

Intellia Therapeutics (NTLA) has reported Enterprise Value for 12 consecutive years, with -$376.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 25.36% year-over-year to -$376.0 million; the TTM figure through Mar 2026 stood at -$376.0 million (up 25.36% YoY), while the FY2025 annual figure was -$449.9 million, up 25.21% from the prior year.
• Enterprise Value advanced to -$376.0 million in Q1 2026 per NTLA's latest filing, from -$449.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$376.0 million in Q1 2026 and bottomed at -$933.5 million in Q1 2023.
• Historically, Enterprise Value has averaged -$690.0 million across 5 years, with a median of -$691.1 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value slumped 65.26% — and 2025, when it jumped 36.34%.
• Intellia Therapeutics' Enterprise Value stood at -$681.1 million in 2022, then tumbled by 33.94% to -$912.2 million in 2023, then soared by 34.06% to -$601.5 million in 2024, then grew by 25.21% to -$449.9 million in 2025, then increased by 16.43% to -$376.0 million in 2026.
• Business Quant data shows NTLA's Enterprise Value at -$376.0 million in Q1 2026, -$449.9 million in Q4 2025, and -$511.0 million in Q3 2025.